Crohn's Disease
Infliximab retreatment results in remission in 35% of patients with Crohn’s disease
After previously discontinuing infliximab, 35% of patients with Crohn’s disease achieved remission at 26 weeks with drug retreatment, according to a study published in The American Journal of Gastroenterology.
Parental use of 5-ASA for IBD before conception, during pregnancy safe for offspring
Paternal and maternal use of 5-aminosalicylic acid for treatment of Crohn’s disease or ulcerative colitis before conception and during pregnancy is safe, based on offspring outcomes in a nationwide Danish cohort study.
Men who have sex with men twice as likely to be diagnosed with IBD
Men who have sex with men were more than twice as likely to develop inflammatory bowel disease compared with men who have sex with women when engaging in “high-risk” sexual activity, according to research published in Gut.
Top 7 in FDA news: Approvals for diarrhea relief, endoscopic devices, Crohn’s treatment
Healio presents the following collection of FDA news related to gastroenterology, including the approval of generic diarrhea relief tablets, treatment for acid sphingomyelinase deficiency and biliary tract cancer, and more.
Q&A: Education, advocacy critical for young adults with IBD ‘to thrive’
Adolescents and young adults with inflammatory bowel diseases are a growing demographic with more than 25% of patients diagnosed before age 16, according to research published in Inflammatory Bowel Diseases.
IBD patients should ‘not delay their infusion’ if stable with COVID-19 infection
Use of biologics did not worsen stable SARS-CoV-2 infection in patients with inflammatory bowel disease if given within 2 weeks of virus detection, according to research published in Clinical Gastroenterology and Hepatology.
Cesarean delivery increases offspring’s risk for Crohn’s disease
People who were delivered by cesarean section were more likely to receive a Crohn’s disease diagnosis later in life compared with their vaginally delivered counterparts, according to a population-based cohort study conducted in Sweden.
FDA approves citrate-free, high concentration formulation of Humira biosimilar
The FDA has approved a citrate-free, 100 mg/mL formulation of the Humira biosimilar Hadlima, according to a statement released by Samsung Bioepis and Organon.
Patients with severe childhood-onset IBD earned ‘markedly’ less in early adulthood
Individuals with severe childhood-onset inflammatory bowel disease, who underwent surgery or long-term inpatient care, had 16% lower occupational earnings from age 20 to 30 years compared with the general population, according to research.
Heavy consumption of sugar-sweetened beverages linked to higher IBD risk
Excessive intake of sugar-sweetened beverages may increase the risk for inflammatory bowel disease, according to research published in Alimentary Pharmacology and Therapeutics.